D.A. Davidson & CO. Sold 375 Shares of Icon Plc (ICLR)

D.A. Davidson & CO. Sold 375 Shares of Icon Plc (ICLR)

D.A. Davidson & CO. decreased its holdings in Icon Plc (NASDAQ:ICLR) by 7.9% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 4,380 shares of the medical research company’s stock after selling 375 shares during the quarter. D.A. Davidson & CO.’s holdings in Icon were worth $566,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. WCM Investment Management CA lifted its position in shares of Icon by 7.9% during the 3rd quarter. WCM Investment Management CA now owns 5,000,711 shares of the medical research company’s stock worth $768,860,000 after buying an additional 367,131 shares in the last quarter. Clearbridge Investments LLC lifted its position in shares of Icon by 9.8% during the 3rd quarter. Clearbridge Investments LLC now owns 2,211,986 shares of the medical research company’s stock worth $340,093,000 after buying an additional 198,271 shares in the last quarter. Acadian Asset Management LLC lifted its position in shares of Icon by 0.4% during the 3rd quarter. Acadian Asset Management LLC now owns 2,181,795 shares of the medical research company’s stock worth $335,450,000 after buying an additional 8,880 shares in the last quarter. Massachusetts Financial Services Co. MA lifted its position in shares of Icon by 12.9% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 1,070,319 shares of the medical research company’s stock worth $164,561,000 after buying an additional 121,970 shares in the last quarter. Finally, Janus Henderson Group PLC lifted its position in shares of Icon by 5.0% during the 3rd quarter. Janus Henderson Group PLC now owns 788,206 shares of the medical research company’s stock worth $121,140,000 after buying an additional 37,851 shares in the last quarter. 88.86% of the stock is currently owned by institutional investors and hedge funds.

Shares of ICLR stock opened at $139.37 on Friday. The company has a quick ratio of 2.17, a current ratio of 2.17 and a debt-to-equity ratio of 0.26. Icon Plc has a 12-month low of $104.85 and a 12-month high of $155.33. The company has a market cap of $7.56 billion, a PE ratio of 25.86, a P/E/G ratio of 1.75 and a beta of 0.71.

Several research firms have commented on ICLR. UBS Group set a $136.00 target price on shares of Icon and gave the stock a “sell” rating in a research report on Saturday, October 27th. Zacks Investment Research cut shares of Icon from a “hold” rating to a “sell” rating in a research report on Tuesday, January 8th. Evercore ISI raised shares of Icon from an “in-line” rating to an “outperform” rating in a research report on Friday, October 26th. Mizuho raised shares of Icon from a “neutral” rating to a “buy” rating and lifted their target price for the stock from $146.00 to $150.00 in a research report on Friday, January 25th. Finally, BidaskClub cut shares of Icon from a “strong-buy” rating to a “buy” rating in a research report on Saturday, January 5th. Two analysts have rated the stock with a sell rating and ten have issued a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average target price of $153.11.

About Icon

ICON Public Limited Company, a clinical research organization, provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries in Ireland, rest of Europe, the United States, and internationally. It specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.

Further Reading: Find a Trading Strategy That Works

Related posts

Leave a Comment